DK1409544T3 - Humane DR4-antistoffer og anvendelser deraf - Google Patents

Humane DR4-antistoffer og anvendelser deraf

Info

Publication number
DK1409544T3
DK1409544T3 DK02805988T DK02805988T DK1409544T3 DK 1409544 T3 DK1409544 T3 DK 1409544T3 DK 02805988 T DK02805988 T DK 02805988T DK 02805988 T DK02805988 T DK 02805988T DK 1409544 T3 DK1409544 T3 DK 1409544T3
Authority
DK
Denmark
Prior art keywords
antibodies
human
kits
diagnosis
articles
Prior art date
Application number
DK02805988T
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1409544T3 publication Critical patent/DK1409544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
DK02805988T 2001-07-03 2002-06-29 Humane DR4-antistoffer og anvendelser deraf DK1409544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30322001P 2001-07-03 2001-07-03
PCT/US2002/020712 WO2003066661A2 (en) 2001-07-03 2002-06-29 Human dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK1409544T3 true DK1409544T3 (da) 2009-10-26

Family

ID=27734188

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02805988T DK1409544T3 (da) 2001-07-03 2002-06-29 Humane DR4-antistoffer og anvendelser deraf

Country Status (14)

Country Link
US (2) US7252994B2 (da)
EP (2) EP1409544B1 (da)
JP (1) JP4509570B2 (da)
AT (1) ATE433996T1 (da)
AU (2) AU2002366430B2 (da)
CA (1) CA2451680C (da)
CY (1) CY1110505T1 (da)
DE (1) DE60232660D1 (da)
DK (1) DK1409544T3 (da)
ES (1) ES2328234T3 (da)
HK (1) HK1065323A1 (da)
IL (1) IL159527A0 (da)
PT (1) PT1409544E (da)
WO (1) WO2003066661A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
ES2239886B1 (es) * 2003-11-05 2006-12-16 Universidad De Barcelona Metodo y aparato para la determinacion de la viabilidad celular.
AU2012200602B2 (en) * 2004-08-06 2012-11-08 Genentech, Inc. Assays and methods using biomarkers
CN102978277A (zh) 2004-08-06 2013-03-20 健泰科生物技术公司 使用生物标志的测定法和方法
KR101235479B1 (ko) 2004-08-06 2013-02-20 제넨테크, 인크. 바이오마커를 사용한 분석 및 방법
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
CA2619759A1 (en) * 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to ap02l/trail by testing for galnac-t14 expression in cells/tissues
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20120144504A1 (en) * 2005-10-16 2012-06-07 Yeda Research And Development Co. Ltd. Caspase-8 and skin disease
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
ATE522518T1 (de) 2006-05-31 2011-09-15 Takeda San Diego Inc Indazol- und isoindolderivate als glucokinaseaktivierende stoffe
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CA2802349A1 (en) * 2010-06-16 2011-12-22 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Anti-dr4 agonist antibodies
EP3559049A4 (en) 2011-10-28 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
AU2015337858B2 (en) 2014-10-29 2020-09-24 Teva Pharmaceuticals Australia Pty Ltd. Interferon alpha2b variants
JP6869553B2 (ja) * 2015-10-30 2021-05-12 ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
CA3007033A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-dr5 antibodies and methods of use thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
WO1992015698A1 (en) 1991-03-11 1992-09-17 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JP3611856B2 (ja) * 1994-02-04 2005-01-19 ベーイーオー・メリュー 多発性硬化症に関与するｍｓｒｖ１ウイルスおよびｍｓｒｖ２病因性及び／又は感染性の作因、核酸成分およびその応用
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
EP2230307A1 (en) 1996-10-25 2010-09-22 Human Genome Sciences, Inc. Neutrokine alpha
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6342363B1 (en) * 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
NZ508381A (en) 1997-03-17 2002-09-27 Human Genome Sciences Inc Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
WO1998046751A1 (en) 1997-04-16 1998-10-22 Amgen Inc. Osteoprotegerin binding proteins and receptors
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
AU9013998A (en) 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
CA2299619A1 (en) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
WO1999009165A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
WO1999037684A1 (en) 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
PT1086138E (pt) 1998-06-12 2010-01-04 Genentech Inc Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
JP4589586B2 (ja) 1999-05-28 2010-12-01 ジェネンテック， インコーポレイテッド Ｄｒ４抗体とその利用
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
JP3665316B2 (ja) * 2001-05-18 2005-06-29 麒麟麦酒株式会社 抗ｔｒａｉｌ−ｒ抗体
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
PL216750B1 (pl) 2001-11-01 2014-05-30 Uab Research Foundation Zastosowanie przeciwciał selektywnych dla receptora liganda indukującego apoptozę pokrewnego czynnikowi martwicy nowotworu i innych czynników terapeutycznych do leczenia nowotworu oraz kompozycja zawierająca takie przeciwciała i inne czynniki terapeutyczne
AU2002352676A1 (en) 2001-11-14 2003-05-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
AU2002366430B2 (en) 2008-09-18
US7744881B2 (en) 2010-06-29
ATE433996T1 (de) 2009-07-15
CA2451680A1 (en) 2003-08-14
IL159527A0 (en) 2004-06-01
WO2003066661A3 (en) 2003-11-27
JP4509570B2 (ja) 2010-07-21
EP1409544A2 (en) 2004-04-21
CY1110505T1 (el) 2015-04-29
US7252994B2 (en) 2007-08-07
AU2002366430A1 (en) 2003-09-02
EP1409544B1 (en) 2009-06-17
US20040147725A1 (en) 2004-07-29
EP1409544A4 (en) 2005-11-09
AU2008260311A1 (en) 2009-01-15
EP2192130A1 (en) 2010-06-02
ES2328234T3 (es) 2009-11-11
PT1409544E (pt) 2009-09-16
DE60232660D1 (de) 2009-07-30
JP2005517021A (ja) 2005-06-09
CA2451680C (en) 2011-04-19
WO2003066661A2 (en) 2003-08-14
US20080233646A1 (en) 2008-09-25
HK1065323A1 (en) 2005-02-18

Similar Documents

Publication Publication Date Title
DK1409544T3 (da) Humane DR4-antistoffer og anvendelser deraf
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO20061736L (no) Krystallform av epotilon B
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
SE9904377D0 (sv) Pharmaceutical combinations
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE494307T1 (de) Neoplasma-spezifische antikörper und deren verwendungen
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
DK0958290T3 (da) 1,4-Dihydropyridinderivater og terapeutisk anvendelse heraf
CY1115126T1 (el) Μεθοδος και εμβολιο που περιλαμβανει συμπολυμερες 1 για θεραπεια ψυχιατρικων διαταραχων